This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Linda A. Hershey, MD PhD
Department of Neurology

James J. Scillian, PhD
Department of Pathology University Hospitals Cleveland, OH 44106

John L. Trotter, MD
Department of Neurology Washington University School of Medicine St Louis, MO 63110

Arch Neurol. 1984;41(5):473.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Caroscio and others¹ have examined CSF from an extensive series of patients with multiple sclerosis (MS) and other diseases. The results of their quantitative CSF IgG measurements largely support our findings² and those of others. We would like to respond to their implied criticism of our low rate (3.5%) of false-positive IgG index results among 160 patients with other neurologic diseases. Contrary to their speculation, this result was not obtained through lack of "blinding." The technicians performing the assays were unaware of the patients' clinical diagnoses. The investigator reviewing the charts was usually unaware of the IgG data. In calculating this figure, we eliminated the data from patients with CNS infections or immunologic disorders (40% of those patients had elevated CSF IgG indexes). Summing the data from these "control" groups, our false-positive rate averaged 11%, which is the same as that reported by Link and . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?